BACKGROUND:
Cryptosporidium spp
. is a protozoan parasite that infects many vertebrate animals, including humans. Since
Cryptosporidium spp
. can cause chronic life-threatening diarrhea and severe malabsorption in immunocompromised patients, we investigated the prevalence of this parasite among patients undergoing chemotherapy for malignant solid tumors.
OBJECTIVE:
Investigate the prevalence of
Cryptosporidium spp
. in stool samples.
DESIGN:
Cross-sectional.
SETTING:
Tertiary care.
PATIENTS AND METHODS:
Stool samples were collected from adult patients with malignant solid tumors receiving chemotherapy and diarrhea.
Cryptosporidium spp
. prevalence was determined using Ziehl–Neelsen staining, ELISA, and real-time PCR targeting of the
COWP
gene.
MAIN OUTCOME MEASURE:
The prevalence of
Cryptosporidium spp
. in patients undergoing chemotherapy for malignant solid tumors.
SAMPLE SIZE:
94
RESULTS:
The prevalence was 2.1% (2/94), 5.3% (5/94), and 5.3% (5/94) as detected by Ziehl–Neelsen staining, real-time PCR and ELISA, respectively. The prevalence reached 8.5% (8/94) using all results obtained from the three methods. Among eight positive stool samples, four were positive by at least two different methods (Ziehl–Neelsen staining-ELISA or ELISA-real-time PCR) whereas the remaining four were positive by either ELISA or real-time PCR.
CONCLUSION:
These findings show the risk of cryptosporidiosis in cancer patients and the necessity to use at least two diagnostic methods during the diagnosis of cryptosporidiosis to reach more accurate and trustworthy results.
LIMITATIONS:
Further studies with a larger sample size are recommended.
CONFLICT OF INTEREST:
None.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.